Structure Therapeutics (GPCR) Net Cash Flow (2022 - 2026)
Structure Therapeutics (GPCR) posted quarterly Net Cash Flow of -$483.5 million for Q1 2026, down 2680.55% year-over-year from $18.7 million in Q1 2025, and down 169.39% quarter-over-quarter from $696.7 million in Q4 2025.
Structure Therapeutics (GPCR) Net Cash Flow (2022 - 2026) Analysis & Trends
Structure Therapeutics' Net Cash Flow history runs 5 years deep, the most recent figure standing at -$483.5 million for Q1 2026.
- In Q1 2026, Net Cash Flow fell 2680.55% year-over-year to -$483.5 million; the TTM figure through Mar 2026 stood at $164.0 million (up 202.16% YoY), while the FY2025 annual figure was $630.1 million, up 1486.47% from the prior year.
- Net Cash Flow for Q1 2026 stood at -$483.5 million, down from $696.7 million in the prior quarter.
- The five-year high for Net Cash Flow was $696.7 million in Q4 2025, with the low at -$483.5 million in Q1 2026.
- The 5-year median for Net Cash Flow is -$5.1 million (2025), against an average of $12.4 million.
- The sharpest annual moves came in 2025 and 2026: Net Cash Flow jumped 26692.02% in 2025, then plunged 2680.55% in 2026.
- Structure Therapeutics' Net Cash Flow stood at -$2.0 million in 2022, then jumped by 4055.82% to $79.2 million in 2023, then tumbled by 103.31% to -$2.6 million in 2024, then surged by 26692.02% to $696.7 million in 2025, then plunged by 169.39% to -$483.5 million in 2026.
- Business Quant data shows GPCR's Net Cash Flow at -$483.5 million in Q1 2026, $696.7 million in Q4 2025, and -$44.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Structure Therapeutics | 11.65 Bn | 11.65 Bn | - | -43.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -43.53 Mn |
| Jun 30, 2026 | -43.53 Mn |
| Mar 31, 2026 | -483.46 Mn |
| Mar 31, 2026 | -483.46 Mn |
| Dec 31, 2025 | 696.71 Mn |
| Dec 31, 2025 | 696.71 Mn |
| Sep 30, 2025 | -44.11 Mn |
| Sep 30, 2025 | -44.11 Mn |
| Jun 30, 2025 | -5.10 Mn |
| Jun 30, 2025 | -5.10 Mn |
| Mar 31, 2025 | -17.39 Mn |
| Mar 31, 2025 | -17.39 Mn |
| Dec 31, 2024 | -2.62 Mn |
| Dec 31, 2024 | -2.62 Mn |
| Sep 30, 2024 | -209.50 Mn |
| Sep 30, 2024 | -209.50 Mn |
| Jun 30, 2024 | 283.80 Mn |
| Jun 30, 2024 | 283.80 Mn |
| Mar 31, 2024 | -31.96 Mn |
| Mar 31, 2024 | -31.96 Mn |